Schering Coricidin HBP "Call to Action" Materials Going Out To Physicians
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough HealthCare Products began sending "Providers' Care Package[s]" to physicians nationwide Sept. 14 in a campaign highlighting three of its cough, cold and flu products that do not contain a decongestant.
You may also be interested in...
Schering-Plough Coricidin repositioning targets hypertension concerns with decongestants.
CORICIDIN COUGH/COLD LINE REPOSITIONING TARGETS HYPERTENSION CONCERNS by highlighting the fact three of the products do not contain decongestant ingredients such as pseudoephedrine/ephedrine, phenylephrine and phenylpropanolamine that may cause problems for those with high blood pressure or interfere with medication for the condition. Schering-Plough has repackaged its Coricidin Cold & Flu Tablets, Cold & Cough Tablets and NightTime Cold & Cough Liquid and renamed the line Coricidin HBP. The products are expected to reach stores by the end of January.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands